Novartis

Novartis NVSEF Stock

$159.45   0.119303%
Add to favorites
Market Cap
$301.14B
LOW - HIGH [24H]
$136.10 - $136.10
VOLUME [24H]
$20.00
P/E Ratio
30.42
Earnings per share
$5.24
ISIN
CH0012005267
Price   Prediction

Novartis Price Chart

Sorry, that's all we've gotfor now...

Novartis (NVSEF) stock price today is 159.45 USD on OTC Markets OTCPK (+0.12% on the day). Updated .

Novartis NVSEF Financial and Trading Overview

Novartis stock price 159.45 USD
Previous Close 159.26 USD
Open 136.1 USD
Bid 157.58 USD x 70000
Ask 165.04 USD x 30000
Day's Range 136.1 - 136.1 USD
52 Week Range 123.69 - 171.29 USD
Volume 20 USD
Avg. Volume 33.32K USD
Market Cap 301.14B USD
Beta (5Y Monthly) 0.453
PE Ratio (TTM) 30.42939
EPS (TTM) 5.24 USD
Forward Dividend & Yield 4.73 (2.97%)
Ex-Dividend Date March 10, 2026
1y Target Est N/A

NVSEF Valuation Measures

Enterprise Value 340.91B USD
Trailing P/E 30.42939
Forward P/E N/A
PEG Ratio (5 yr expected) 3.79
Price/Sales (ttm) 5.249652
Price/Book (mrq) 8.088982
Enterprise Value/Revenue 5.943
Enterprise Value/EBITDA 14.165

Trading Information

Novartis Stock Price History

Beta (5Y Monthly) 0.453
52-Week Change 25.27%
S&P500 52-Week Change 12.07%
52 Week High 171.29 USD
52 Week Low 123.69 USD
50-Day Moving Average 146.91 USD
200-Day Moving Average 151.38 USD

NVSEF Share Statistics

Avg. Volume (3 month) 33.32K USD
Avg. Daily Volume (10-Days) 81.38K USD
Shares Outstanding 1.89B
Float 1.84B
Short Ratio N/A
% Held by Insiders 2.11%
% Held by Institutions 46.39%
Shares Short N/A
Short % of Float N/A
Short % of Shares Outstanding N/A

Dividends & Splits

Trailing Annual Dividend Rate 4.666
Trailing Annual Dividend Yield 2.92%
5 Year Average Dividend Yield 349.00%
Payout Ratio 0.8707
Last Split Factor 1055:1000

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2025
Most Recent Quarter (mrq) September 30, 2026
Next Fiscal Year End December 31, 2026

Profitability

Profit Margin 17.48%
Operating Margin (ttm) 33.98%
Gross Margin 75.20%
EBITDA Margin 41.95%

Management Effectiveness

Return on Assets (ttm) 10.85%
Return on Equity (ttm) 24.32%

Income Statement

Revenue (ttm) 57.36B USD
Revenue Per Share (ttm) 30.1 USD
Quarterly Revenue Growth (yoy) 4.70%
Gross Profit (ttm) 43.14B USD
EBITDA 24.07B USD
Net Income Avi to Common (ttm) 10.03B USD
Diluted EPS (ttm) 5.24
Quarterly Earnings Growth (yoy) -69.39%

Balance Sheet

Total Cash (mrq) 8.87B USD
Total Cash Per Share (mrq) 4.7 USD
Total Debt (mrq) 48.31B USD
Total Debt/Equity (mrq) 128.61 USD
Current Ratio (mrq) 0.884
Book Value Per Share (mrq) 19.712

Cash Flow Statement

Operating Cash Flow (ttm) 17.33B USD
Levered Free Cash Flow (ttm) 11.27B USD

Profile of Novartis

Country United States
State N/A
City Basel
Address Lichtstrasse 35
ZIP 4056
Phone 41 61 324 11 11
Website https://www.novartis.com
Industry Drug Manufacturers - General
Sector(s) Healthcare
Full Time Employees 75267

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure; Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6; Promacta/Revolade for immune thrombocytopenia (ITP), thrombocytopenia, and aplastic anemia patients; Tafinlar+Mekinist, an oral combination therapy to treat cancer patients; and Jakavi for treating myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease. It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in chronic and/or accelerated phase; Xolair for treating allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Stills disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma to treat genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran) to reduce LDL cholesterol. Novartis AG has a strategic alliance with CAS for enhancing reaction data accessibility and supporting AI-enabled research. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

Q&A For Novartis Stock

What is a current NVSEF stock price?

Novartis NVSEF stock price today per share is 159.45 USD.

How to purchase Novartis stock?

You can buy NVSEF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Novartis?

The stock symbol or ticker of Novartis is NVSEF.

Which industry does the Novartis company belong to?

The Novartis industry is Drug Manufacturers - General.

How many shares does Novartis have in circulation?

The max supply of Novartis shares is 1.89B.

What is Novartis Price to Earnings Ratio (PE Ratio)?

Novartis PE Ratio is 30.42939000 now.

What was Novartis earnings per share over the trailing 12 months (TTM)?

Novartis EPS is 5.24 USD over the trailing 12 months.

Which sector does the Novartis company belong to?

The Novartis sector is Healthcare.

$2.16T
Total marketcap
$70.56B
Total volume
BTC 57.93%   •   ETH 9.96%
Dominance
Select currency